SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC Product Launches 8-K Filing 2024 - Clinical Trial Update Shuttle Pharmaceuticals announced that the first three patients have been successfully dosed in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, with the drug receiving Orphan Drug Designation from the FDA.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC